{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:56:20Z","timestamp":1790571380030,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide is increasing rapidly worldwide, and the pancreatic and biliary safety of these drugs has been a concern. This study was based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) to evaluate the pancreatic and biliary adverse event reporting signals of liraglutide, semaglutide, tirzepatide and dulaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the reporting patterns of pancreatic and biliary adverse events for liraglutide, semaglutide, dulaglutide, and tirzepatide, and to identify signals in both organ systems within a single framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective disproportionality analysis of individual case safety reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS data from Q3\u20132009 through Q3\u20132025 were extracted, and deduplicated ICSRs were used as the unit of analysis. Reporting odds ratios (RORs) and information components (ICs) were computed at composite and Preferred Term levels; signals required the lower 95% confidence bound for the ROR to exceed 1 and IC025 to exceed 0. Metformin and sodium-glucose cotransporter-2 inhibitors were included as contextual benchmarks. Analyses were stratified by brand (diabetes\/obesity indication), sex, age, and reporter type, and time to onset was examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A disproportionality signal for pancreatic adverse events was observed for all four study drugs, but the control drugs metformin and SGLT2i also showed positive signals. For biliary events, all four study drugs showed signals, whereas the two control drugs showed no signals. After stratification by brand, the pancreatic signal remained for brands with diabetes indications, while the signal was weaker for brands with obesity indications. After excluding the cases of biliary tract co-reporting, the pancreatic signal still existed. Median time to onset ranged from 85.5 to 136 days for pancreatic events and from 146.5 to 320 days for biliary events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both GLP-1RAs and tirzepatide are associated with disproportionate reporting of pancreatic and biliary adverse events in FAERS. Signals are influenced by indication, reporting behavior, and time effects and cannot be used to estimate incidence or prove causality. These signals suggest the need for further validation in real-world cohort studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1941948","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:29:24Z","timestamp":1790569764000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuanbin","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, The Seventh Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The Seventh Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The Seventh Medical Center, Chinese PLA General Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zike","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2512436","article-title":"Diabetes mellitus and cardiovascular disease: Exploring epidemiology, pathophysiology, and treatment strategies","volume":"25","author":"Siam","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Buse","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li","year":"2014","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: Data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1461398","article-title":"Association between different GLP-1 receptor agonists and acute pancreatitis: Case series and real-world pharmacovigilance analysis","volume":"15","author":"Guo","year":"2024","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1557691","article-title":"Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: A real-world pharmacovigilance analysis using the FAERS database","volume":"16","author":"Tao","year":"2025","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: Pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01869-4","article-title":"Real-world safety of maribavir: A retrospective study based on signal detection in the FDA adverse event reporting system","volume":"47","author":"Gong","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2328321","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for daratumumab","volume":"23","author":"Yun","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1509310","article-title":"Safety assessment of tolvaptan: Real-world adverse event analysis using the FAERS database","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1481114","article-title":"Signal mining and analysis of ripretinib adverse events: A real-world pharmacovigilance analysis based on the FAERS database","volume":"16","author":"Hu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"34673","DOI":"10.1038\/s41598-025-02394-0","article-title":"Disproportionality analysis of GLP-1 receptor agonists combined with metformin based on the FAERS database","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: A real-world study based on the US FDA adverse event reporting system database","volume":"42","author":"Wu","year":"2022","journal-title":"Clin Drug Investig"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis","volume":"316","author":"Palmer","year":"2016","journal-title":"Jama"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2309223","article-title":"Utilizing temporal pattern of adverse event reports to identify potential late-onset adverse events","volume":"23","author":"Kim","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"20420188251406456","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 receptor agonists and gallbladder disease risk: Insights into molecular mechanisms and clinical implications","volume":"16","author":"Ram\u00edrez-Mej\u00eda","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: A systematic review and meta analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann Saudi Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.1522","article-title":"Association between incretin-based drugs and the risk of acute pancreatitis","volume":"176","author":"Azoulay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248734","article-title":"The effect of semaglutide on pancreatic \u03b2-cell function in adults with type 2 diabetes: A systematic review and meta-analysis","volume":"14","author":"Abusedera","year":"2025","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","article-title":"GLP-1-based therapies for type 2 diabetes: From single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation","volume":"17","author":"Movahednasab","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11595370-000000000-00000","article-title":"Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus : Focus on bile acid sequestrants","volume":"32","author":"Holst","year":"2012","journal-title":"Clin Drug Investig"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2021.102212","article-title":"TEDAR: Temporal dynamic signal detection of adverse reactions","volume":"122","author":"Aparo","year":"2021","journal-title":"Artif Intell Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12933-025-02986-0","article-title":"Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: Observations from a federated research network","volume":"24","author":"Tartaglia","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2423679","article-title":"Drug-induced noninfectious myocarditis: A disproportionality analysis of the FAERS database","volume":"24","author":"Yan","year":"2025","journal-title":"Expert Opin Drug Saf"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1941948\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:29:25Z","timestamp":1790569765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1941948\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":36,"alternative-id":["10.3389\/fendo.2026.1941948"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1941948","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1941948"}}